EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Side Branch Additional Treatment for Coronary Bifurcation Lesion Revascularization

Bernard Chevalier, Luc Cornillet, Frederic Bouisset, Laurent Delorme, Stephane Champagne, Philippe Brunel, Katrien Blanchart, Giuseppe Ferrante, Manuel Pan, Pedro Goncalves, Antoinette Neylon, Benoit Lattuca und 1 weitere

JACC: Cardiovascular Interventions · 2026-04 · 19 (8) · 961-972

DOI: 10.1016/j.jcin.2026.02.012 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026-04. Verfasst von Bernard Chevalier und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Ramsay Santé, Massy, France. Electronic address: b.chevalier@angio-icps.com. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Coronary Artery Disease, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Medtronic Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although provisional stenting is the recommended strategy for most coronary bifurcation lesions, the clinical benefit of additional side branch (SB) intervention remains debated. OBJECTIVES: The aim of this study was to determine whether a conservative strategy without systematic SB intervention (SBI) is noninferior to systematic SB intervention regarding periprocedural events. METHODS: The multicenter, international KISS (Keep Bifurcation Single Stenting Simple) trial randomized patients with non-left main bifurcation lesions to 2 groups: no SBI or SBI following main branch stenting with the Resolute Onyx drug-eluting stent and a proximal optimization technique without impairment of SB flow. The primary endpoint was periprocedural myocardial infarction (MI) or myocardial injury, according to the Academic Research Consortium 2 definition. Secondary endpoints included procedural complications and 12-month clinical outcomes, including target lesion failure, defined as the composite of cardiac death, target vessel MI, and target lesion revascularization. RESULTS: Among the 616 included patients, 81% were treated for chronic coronary disease, and the bifurcation mainly involved was between the left anterior descending coronary artery and the diagonal. In the no-SBI group, an intervention on the SB was required in 2.0% of patients (n = 6). Periprocedural MI or myocardial injury occurred in 4.1% (n = 11) in the no-SBI group vs 5.7% (n = 16) in the SBI group (P < 0.001 for noninferiority; P = 0.38 for superiority). There was no significant interaction with age, sex, Medina classification, or SB residual stenosis. Procedure time, radiation dose, and contrast use were significantly lower in the no-SBI group. Procedural complications were rare, but SB dissection was more frequently observed in the SBI group (2.9% vs 0.0%; P = 0.004). There was no difference in target lesion failure at 1 year (4.9% [n = 15] vs 6.4% [n = 20] in the no-SBI and SBI groups respectively; P = 0.442). CONCLUSIONS: The KISS trial demonstrates that a conservative strategy without systematic SB intervention is associated with very rare procedural complications and is noninferior to a systematic SB intervention regarding periprocedural MI and myocardial injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsCoronary Artery DiseasePercutaneous Coronary InterventionHumansFemaleTreatment OutcomeMaleMyocardial InfarctionTime FactorsAgedMiddle AgedRisk FactorsCoronary AngiographyProsthesis Design

Stichwörter der Autor:innen

KISSbifurcationmyocardial infarctionmyocardial injuryperiprocedural complicationsside branch

Autor:innen und Institutionen

  • Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Ramsay Santé, Massy, France. Electronic address: b.chevalier@angio-icps.com.
  • Cardiology Department, Nîmes University Hospital, Montpellier University, ACTION Study Group, Nîmes, France.
  • Department of Cardiology, Toulouse University Hospital, Toulouse, France.
  • Department of Cardiology, Clinique du Pont de Chaume, Montauban, France.
  • Hôpital Privé Claude Galien ICPS, Ramsay Santé, Quincy-Sous-Sénart, France.
  • Hôpital Privé Dijon Bourgogne, Dijon, France.

Förderung

  • Medtronic Inc

Zitieren

APA

Chevalier, B., Cornillet, L., Bouisset, F., Delorme, L., Champagne, S., Brunel, P., Blanchart, K., Ferrante, G., Pan, M., Goncalves, P., Neylon, A., Lattuca, B., & KISS Trial Group (2026). Side Branch Additional Treatment for Coronary Bifurcation Lesion Revascularization. JACC: Cardiovascular Interventions, 19(8), 961-972. https://doi.org/10.1016/j.jcin.2026.02.012

Vancouver

Chevalier B, Cornillet L, Bouisset F, Delorme L, Champagne S, Brunel P, et al. Side Branch Additional Treatment for Coronary Bifurcation Lesion Revascularization. JACC: Cardiovascular Interventions. 2026;19(8):961-972. doi:10.1016/j.jcin.2026.02.012

BibTeX
@article{Chevalier2026,
  author = {Chevalier, Bernard and Cornillet, Luc and Bouisset, Frederic and Delorme, Laurent and Champagne, Stephane and Brunel, Philippe and Blanchart, Katrien and Ferrante, Giuseppe and Pan, Manuel and Goncalves, Pedro and Neylon, Antoinette and Lattuca, Benoit and KISS Trial Group, KISS Trial Group},
  title = {Side Branch Additional Treatment for Coronary Bifurcation Lesion Revascularization},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {961--972},
  doi = {10.1016/j.jcin.2026.02.012}
}
Kostenlos starten →